Team:Queens/Project

From 2009.igem.org

(Difference between revisions)
Line 60: Line 60:
<tr>
<tr>
-
<td align="center">
+
<td align="left">
<p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold">
<p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold">
Part One: Binding System
Part One: Binding System
</p>
</p>
</td>
</td>
-
<td align="center">
+
<td align="left">
<p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold">
<p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold">
Part Two: Effector System
Part Two: Effector System
</p>
</p>
</td>
</td>
-
<td align="center">
+
<td align="left">
<p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold">
<p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold">
Part Three: Cleavage and Termination
Part Three: Cleavage and Termination

Revision as of 04:47, 1 August 2009



Overview


The QGEM project centres on the treatment of atherosclerosis by targeted drug delivery from E.coli. The project is broken down into three major components. The first, and the main, component is the cell membrane protein that allows E.coli to bind to the site of atherosclerotic plaque. The second component is the inducible effector system that produces factors to treat the plaque. The last component is the terminator system that detaches E.coli from the plaque and inhibits proliferation of E.coli in the blood stream.


Part One: Binding System

Part Two: Effector System

Part Three: Cleavage and Termination




Last Updated: May 11, 2009 by Fr3P